Approval is for adults with moderately to severely active disease
MONDAY, Sept. 16, 2024 (HealthDay News) — The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
Tremfya is the first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis. It is approved for administration as a 200-mg induction dose intravenously at weeks 0, 4, and 8 by a health care professional.
The approval is based on results from the phase 2b/3 QUASAR study. Half of patients receiving Tremfya 200 mg subcutaneous (SC) maintenance every four weeks and 45 percent of patients receiving Tremfya 100 mg SC every eight weeks achieved the primary end point of clinical remission at week 44 versus 19 percent of patients receiving placebo. At one year, 34 percent (200 mg) and 35 percent (100 mg) of patients achieved endoscopic remission compared with15 percent receiving placebo.
“Treatment with Tremfya resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining,” David T. Rubin, M.D., from the University of Chicago Medicine and lead investigator for the QUASAR program, said in a statement.
Approval of Tremfya was granted to Johnson & Johnson.
Healthy Lifestyle in Early Childhood Linked to Lower Risk for IBD .jpeg)
Most Adults With Moderate-to-Severe Ulcerative Colitis Ineligible for RCTs 
Emergency Diagnosis Linked to Worse Outcomes for Range of Conditions 
Bowel Urgency in Ulcerative Colitis Linked to Disease-Related Disability 
Lung Disease More Common With Ulcerative Colitis Than Crohn Disease 
Risk for Psychiatric Disorders Begins to Increase Before Diagnosis of IBD 
Crohn Disease Linked to Increased Risk for Periprosthetic Joint Infection 
